ACKNOWLEDGMENTSThe individual contributions of Sorrel Wolowacz and Richard Willke are gratefully acknowledged. We thank all reviewers who commented during our forums at the ISPOR Milan and Amsterdam European Congresses. We especially thank the following individuals who reviewed drafts of the report and submitted written comments. Their feedback has both improved the manuscript and made it an expert consensus ISPOR task force report. Many thanks to Tony Ades, René Allard, Gouri Shankar Bhattacharyya, Lance Brannman, Michael Carter, David Cella, Akriti Chahar, Stephanie Yanjing Chen, Shiva Devarakonda, Salah Ghabri, Linda Gore Martin, Inigo Gorostiza, Thomas Grochtdreis, Michael Hagan, Nadine Hillock, Cynthia Holmes, Shrividya Iyer, Steve Kay, Jeanette Kusel, Ramanath KV, Dawn Lee, Joanna Le niowska, Sophia E. Marsh, Alan Martin, Nicholas Mitsakakis, Sharanya Murty, Nneka Onwudiwe, Guilhem Pietri, G.M. Rabiul Islam, Ghabri Salah, Mihail Samnaliev, Carsten Schousboe, Sarah Shingler, Fatema Turkistani, and Uday Venkat. Finally, many thanks to Theresa Tesoro for her assistance in developing this task force report.
2
AbstractEconomic evaluation conducted in terms of cost per Quality Adjusted Life Year (QALY) provides information that decision makers find useful in many parts of the world. Ideally, clinical studies designed to assess the effectiveness of health technologies would include outcome measures that are directly linked to health utility in order to calculate QALYs. Often this does not happen and, even where it does, clinical studies may be insufficient for a cost-utility assessment. Mapping can solve this problem. It uses an additional dataset to estimate the relationship between outcomes measured in clinical studies and health utility. This bridges the evidence gap between available evidence on the effect of a health technology in one metric and the requirement for decision makers to express it in a different one (QALYs). In 2014, ISPOR established a Good Practices for Outcome Research Task Force for mapping studies. This Task Force Report provides recommendations to analysts undertaking mapping studies, those that use the results in cost utility analysis, and those that need to critically review such studies. The recommendations cover all areas of mapping practice: the selection of datasets for the mapping estimation, model selection and performance assessment, reporting standards, and the use of results including the appropriate reflection of variability and uncertainty. This report is unique because it takes an international perspective, is comprehensive in its coverage of the aspects of mapping practice, and reflects the current state of the art.